​​​Monurol (Fosfomycin Trometamol) receives DCA approval for transrectal prostate biopsy in adult men

January 18, 2024
​The Drug Control Authority (DCA) has approved Monurol (fosfomycin trometamol) (MAL20033481AZ) as a perioperative antibiotic prophylaxis for transrectal prostate biopsy in adult men. The recommended dosage is 1 sachet of Monurol 3g approximately 3 hours before, and 24 hours after the procedure.

About Monurol (Fosfomycin Trometamol)
Monurol contains the active substance fosfomycin in the form of trometamol salt. Fosfomycin is an antibiotic (derived from phosphonic acid) with a bactericidal effect. This is based on inhibition of bacterial cell wall synthesis, blocking one of the first steps of peptidoglycan synthesis.

The recommended dosage for the indication of perioperative antibiotic prophylaxis for transrectal prostate biopsy is 1 sachet of Monurol 3g approximately 3 hours before, and another sachet at 24 hours after the procedure.

EXPLORE FURTHER

Picture
​Air signature purium: A solution for tackling airborne diseases and eliminating harmful particulate air pollution
Picture
​​Tata Consultancy partners with National Cancer Society to create CANSupport app for tackling pediatric cancer
Picture
​Gobi partners onboards Care Concierge to the Khazanah-backed Gobi Dana Impak Ventures fund
Picture
Ramsay Sime Darby Health Care celebrates double win at Healthcare Asia Awards
Picture
​University Malaya Medical Centre inks deal to make Uniportal VATS more affordable for lung cancer patients